Skip to content
ClinCalc Pro
Menu
Obstetrics & Gynaecology Strong — NICE NG207

Bishop Score

Bishop score (1964) of cervical readiness for induction of labour. NICE NG207: 6 or less → cervical ripening methods; more than 6 → amniotomy and oxytocin; 8 or more generally indicates a ripe cervix.

How to use & interpret

The Bishop score assesses how favourable the cervix is for induction of labour, scoring cervical dilation, effacement, station, consistency and position. A higher score means a more favourable cervix and a higher chance of successful induction.

Broadly, a score ≥8 suggests the cervix is favourable (induction likely to succeed, comparable to spontaneous labour), while a low score (often <6) suggests cervical ripening (e.g. prostaglandins or a balloon catheter) may be needed first. Thresholds vary by local protocol.

Score interpretation

Unfavourable Cervix (≤ 6) 0–6

Bishop score 6 or less: unfavourable cervix (NICE NG207).

→ Pre-induction cervical ripening — Adults: vaginal prostaglandin E2 (dinoprostone 3mg ×2, 6h apart), low-dose oral misoprostol, or a mechanical method (balloon catheter). Children: use a children's formulary. Reassess Bishop before starting oxytocin.

Score 7 (> 6) 7

Bishop score more than 6 (NICE NG207); below the score of 8 that generally indicates a ripe cervix.

→ Amniotomy and intravenous oxytocin infusion (NICE NG207).

Favourable Cervix (≥ 8) 8–13

Bishop score 8 or more: the cervix is ready; high chance of successful induction.

→ Amniotomy and intravenous oxytocin infusion (NICE NG207).

Interpretation bands for the Bishop Score. Apply clinical judgement and local guidance.

Frequently asked questions

What Bishop score is considered favourable?

A score of 8 or more is generally considered favourable for induction; lower scores often prompt cervical ripening before amniotomy/oxytocin, per local guidance.

References

Related

Curated clinical cross-links plus same-class fallbacks.

Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.